Welcome to our dedicated page for EUDA Health Holdings SEC filings (Ticker: EUDAW), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
EUDA Health Holdings Limited filings document a foreign private issuer with ordinary shares and listed warrants, using Form 6-K reports to disclose material events, Nasdaq listing-compliance notices, capital actions, securities purchase agreements and warrant matters. The filings include disclosures on a board-approved reverse stock split, adjustments to warrant terms, a registered ordinary-share offering under a Form F-3 shelf registration statement, and the repurchase and cancellation of a warrant.
EUDA's regulatory reports also describe its healthcare activities in Asia, including a non-exclusive arrangement to market selected Shenzhen Inno immunotherapies to customers in Malaysia through CK Health Plus Sdn Bhd, with treatments conducted in China.
EUDA Health Holdings Limited has filed a 2026 prospectus supplement for its existing at-the-market equity program, allowing it to sell ordinary shares with an aggregate offering price of up to $10,000,000 through Chardan Capital Markets as sales agent. The company states that no ordinary shares have been sold under this Sales Agreement to date.
The supplement highlights business risks, including uncertainty around plans to work with third parties to establish a longevity clinic in Shenzhen, China, for which no binding agreements or approvals currently exist. It also notes uncertainty around launching an integrated digital health and rewards platform and the future use of QB coin utility cryptocurrency, which is still in development by a third party. EUDA cautions that failure of these initiatives could materially and adversely affect its business and results of operations.
EUDA Health Holdings Ltd amended its annual report describing continued operating losses, a May 8, 2024 acquisition of CK Health Plus Sdn Bhd and significant non-cash impairment charges. The Company reported 37,153,049 ordinary shares outstanding as of December 31, 2024 and recorded a $14,755,560 impairment of intangible assets in 2024.
Management disclosed substantial doubt about the Company’s ability to continue as a going concern within one year, noting recurring losses since 2020, cash of approximately $0.2 million and a need to raise additional financing. The CK Health acquisition was settled with 8,571,428 newly issued shares valued at $15.0 million (at $1.75 per share), plus a contingent 1,000,000-share earnout tied to 2024–2025 net income milestones.
EUDA Health Holdings Limited reports a new agreement with its institutional investor around an existing convertible note. The investor originally agreed to purchase up to $10,000,000 in convertible promissory notes and had already bought a $1,000,000 note that converts into ordinary shares at an 85% discount each time it converts. The company now has delivered 41,620 ordinary shares at a conversion price of $0.901 per share and both parties have mutually waived past breaches of the note and related agreement. In return, the investor agreed not to make further conversions until December 15, 2025, unless EUDA’s Nasdaq closing price reaches $2.00 or higher for three consecutive trading days. EUDA also states it does not intend to purchase any additional notes under the note purchase agreement.
EUDA Health Holdings Limited filed an amended Form 20-F to replace only page F-1 of its original annual report for the year ended December 31, 2024. All other disclosures from the original filing remain unchanged.
The independent auditor issued an unqualified opinion on the 2024 consolidated financial statements, stating they present fairly the company’s financial position and results in conformity with U.S. GAAP. However, the auditor highlighted that EUDA has an accumulated deficit of $50,100,426 and a shareholders’ equity deficit of $2,553,059 as of December 31, 2024, which raises substantial doubt about its ability to continue as a going concern.
As of December 31, 2024, EUDA had 37,153,049 ordinary shares outstanding and is listed on the Nasdaq Stock Market.
EUDA Health Holdings Limited, a foreign private issuer based in Singapore, submitted a Form 6-K for September 2025. The company reports an “Other Events” item and furnished a press release dated September 10, 2025, as Exhibit 99.1.
The report is signed by Interim Chief Financial Officer Vivian Tay on behalf of the company.
EUDA Health Holdings Limited submitted a Form 6-K as a foreign private issuer to furnish a company press release as an exhibit. The report is categorized as an "Other Events" update and is tied to a press release dated September 4, 2025.
The filing is signed on behalf of the company by Interim Chief Financial Officer Vivian Tay, indicating management’s authorization of this disclosure under the Securities Exchange Act of 1934.
EUDA Health Holdings Limited amended a prior report to provide legal support for a previously disclosed financing. The company had entered into a convertible promissory note purchase agreement dated August 1, 2025 with an institutional investor for Notes in an aggregate amount not to exceed $10,000,000. Ordinary shares issuable upon conversion of these Notes will be issued under a prospectus supplement to the company’s Form F-3 registration statement. This amendment files an opinion of counsel and related consent covering the validity of those shares.
EUDA Health Holdings Ltd. (Nasdaq: EUDA) has filed a Form 424(b)(5) prospectus supplement to register up to 5,000,000 ordinary shares underlying a US$10 million one-year convertible note to be sold to Indigo Capital LP in a registered-direct transaction. Notes are issued at a 10 % original-issue discount (net cash ≈ US$9 million; estimated net proceeds after expenses ≈ US$8.98 million) and convert at 85 % of the share’s Nasdaq close on the conversion date, capped at 4.99 % beneficial ownership. A 5-day closing bid below US$2.00 constitutes an “Early Default,” accelerating repayment or conversion; no interest accrues. No public market will exist for the notes.
The financing adds to an already highly dilutive capital structure: 37.16 million shares outstanding, 8.9 million warrants and other convertibles. FY-2024 results showed a US$15.4 million net loss, US$3.4 million working-capital deficit and only US$0.2 million cash. The auditor issued a going-concern warning and management cited material-control weaknesses. Proceeds are earmarked for working capital, M&A and general corporate purposes.
EUDA is pivoting from low-demand medical clinics to wellness services after acquiring CK Health (2.2 % of 2024 revenue) and partnering for stem-cell packages. Two large shareholders control ~53 % of equity, and resale registration rights could pressure the stock. Investors face execution, dilution, and delisting risks offset by near-term liquidity from the note.